Xianle Health announced that the company held the 22nd meeting of the 4th board of directors on July 17, 2026 to review and pass the “Proposal on Investing in the Construction of the Thai Production Base Phase II Project”. In order to seize the rapid growth opportunities for softgels, tablets, and bottled drinks in the Southeast Asia, Australia and New Zealand markets, the company is co-ordinating the planning and construction of the second phase of the project in the existing factory area in Thailand, including a drink workshop, a softgel workshop and a tablet workshop. The current foreign investment amount is no more than 38 million US dollars. The funding source is the company's own funds. The implementing entity is Xianle Health Technology Co., Ltd., and the implementation location is Chonburi Province, Thailand.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.